Navigation Links
Amgen Announces 2013 Third Quarter Dividend
Date:7/26/2013

egulatory developments (domestic or foreign) involving current and future products, sales growth of recently launched products, competition from other products (domestic or foreign), difficulties or delays in manufacturing our products.  In addition, sales of our products are affected by reimbursement policies imposed by third-party payors, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment as well as U.S. legislation affecting pharmaceutical pricing and reimbursement. Government and others' regulations and reimbursement policies may affect the development, usage and pricing of our products.  Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities.  We or others could identify safety, side effects or manufacturing problems with our products after they are on the market. Our business may be impacted by government investigations, litigation and products liability claims. If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S. government, we could become subject to significant sanctions. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors.  We depend on third parties for a significant portion of our manufacturing capacity for the supply of certain of our current and future products and limits on supply may constrain sales of certain of our current products and product candidate development.  In addition, we compete with other companies with respect to some of our marketed products as well as for the discovery and development of new products. Discovery o
'/>"/>
SOURCE Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Amgen and FDA Agree to Modify Nplate® (Romiplostim) Risk Evaluation and Mitigation Strategy
2. Amgen Presents Final Results from the Largest Phase 3 Open-Label Study Assessing the Safety and Efficacy of Nplate® (Romiplostim)
3. Amgen Announces 2012 First Quarter Dividend
4. Kevin Sharer, Amgen Chairman and CEO, Announces Plan to Retire With Robert Bradway to Become CEO on May 23, 2012; Sharer Will Continue as Chairman of the Board Until End of 2012
5. Amgen to Present at the 30th Annual J.P. Morgan Global Healthcare Conference
6. Amgen Announces Webcast of 2011 Fourth Quarter and Full Year Financial Results
7. Amgen to Acquire Micromet
8. Amgen to Present at the Leerink Swann Global Healthcare Conference
9. Amgen Announces 2012 Third Quarter Dividend
10. Amgen Names Ray Jordan Senior Vice President, Corporate Affairs
11. Amgen To Present At The 24th Annual Piper Jaffray Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... (PRWEB) July 25, 2014 At the ... has granted a 60-day extension for the public comment ... Special Rule for Model Aircraft established by Congress as ... 2012. The 60-day extension establishes the new deadline for ... States Department of Transportation/FAA notice published in the Federal ...
(Date:7/24/2014)... -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") announced the ... Phase 3 study of Zerenex (ferric citrate), the Company,s ... of hyperphosphatemia in patients with end-stage renal disease (ESRD) ... delivery with FErric CiTrate in EsrD) was published online ... of Nephrology ( JASN ). , ...
(Date:7/24/2014)... July 24, 2014 Gain recognition ... Supply Chain of the biotech industry. Nominations are ... Awards, brought to you by the Bio ... of supply chain management professionals for the past ... stakeholders of the Biotech industry – Manufacturers, Service ...
(Date:7/24/2014)... , July 24, 2014  Asterias Biotherapeutics, Inc. ... emerging field of regenerative medicine, announced today that ... presentation to investors on Tuesday, July 29, 2014, ... presentation will include an overview of Asterias, business ... webcast, visit http://www.ustream.tv/channel/asterias-biotherapeutics at least 15 ...
Breaking Biology Technology:FAA Grants Comment Extension at the Request of AMA 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 4Call for Submission: BSMA’s Supply Chain Management Innovation Awards 2Call for Submission: BSMA’s Supply Chain Management Innovation Awards 3Asterias Biotherapeutics Announces Live Investor Webcast 2Asterias Biotherapeutics Announces Live Investor Webcast 3Asterias Biotherapeutics Announces Live Investor Webcast 4
... NEW ORLEANS, and RESEARCH TRIANGLE PARK, N.C., Nov. ... presented in vitro data demonstrating that ... not substrates for the human Organic Anion Transporters ... cause nephrotoxicity via this mechanism.  These data, presented ...
... Health Invites Medisafe 1 Technologies to Demonstrate its... -- JERUSALEM, November 16, 2010 ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... ""; BitlyCB.alertResponse = function(data) { var s = ,; var first_result; // Results are keyed by longUrl, so we ...
... SHENYANG, China, Nov. 15, 2010 /PRNewswire-Asia-FirstCall/ -- 3SBio Inc. ... a leading China-based biotechnology company focused on researching, developing, ... financial results for the third quarter ended September 30, ... Highlights: Total net revenues increased ...
Cached Biology Technology:Chimerix's PIM Conjugate Technology Reduces Risk of Nephrotoxicity for CMX001 and CMX157 2Chimerix's PIM Conjugate Technology Reduces Risk of Nephrotoxicity for CMX001 and CMX157 3Chimerix's PIM Conjugate Technology Reduces Risk of Nephrotoxicity for CMX001 and CMX157 4The Israeli Government's Ministry of Health Invites Medisafe 1 Technologies to Demonstrate its Unique Syringe Locking Device Technology 2The Israeli Government's Ministry of Health Invites Medisafe 1 Technologies to Demonstrate its Unique Syringe Locking Device Technology 3The Israeli Government's Ministry of Health Invites Medisafe 1 Technologies to Demonstrate its Unique Syringe Locking Device Technology 4The Israeli Government's Ministry of Health Invites Medisafe 1 Technologies to Demonstrate its Unique Syringe Locking Device Technology 5The Israeli Government's Ministry of Health Invites Medisafe 1 Technologies to Demonstrate its Unique Syringe Locking Device Technology 6The Israeli Government's Ministry of Health Invites Medisafe 1 Technologies to Demonstrate its Unique Syringe Locking Device Technology 7The Israeli Government's Ministry of Health Invites Medisafe 1 Technologies to Demonstrate its Unique Syringe Locking Device Technology 83SBio Inc. Announces Unaudited Third Quarter Results 23SBio Inc. Announces Unaudited Third Quarter Results 33SBio Inc. Announces Unaudited Third Quarter Results 43SBio Inc. Announces Unaudited Third Quarter Results 53SBio Inc. Announces Unaudited Third Quarter Results 63SBio Inc. Announces Unaudited Third Quarter Results 73SBio Inc. Announces Unaudited Third Quarter Results 83SBio Inc. Announces Unaudited Third Quarter Results 93SBio Inc. Announces Unaudited Third Quarter Results 103SBio Inc. Announces Unaudited Third Quarter Results 113SBio Inc. Announces Unaudited Third Quarter Results 123SBio Inc. Announces Unaudited Third Quarter Results 133SBio Inc. Announces Unaudited Third Quarter Results 143SBio Inc. Announces Unaudited Third Quarter Results 153SBio Inc. Announces Unaudited Third Quarter Results 163SBio Inc. Announces Unaudited Third Quarter Results 173SBio Inc. Announces Unaudited Third Quarter Results 18
(Date:7/24/2014)... where electric cars ply silent freeways, solar panels blanket ... the earth, from howling winds and from the blazing ... it is technically and economically feasible to convert California,s ... energy. Published in Energy , the plan shows ... supply in California that could create tens of thousands ...
(Date:7/24/2014)... has its own microbial terroir, meaning the microbial populations ... in the product, creating the final flavor according to ... Applied and Environmental Microbiology . This is the first ... sake brewery. , Many sake makers inoculate with ... Mills of the University of California, Davis, but he ...
(Date:7/24/2014)... O.D., a low vision specialist at The University of ... has been awarded a grant to help Harris County ... medication or surgery. , Even with corrective lenses, many ... However, there are a variety of low vision devices, ... offset their vision loss. , Iyer is using the ...
Breaking Biology News(10 mins):Stanford study shows how to power California with wind, water and sun 2Stanford study shows how to power California with wind, water and sun 3Stanford study shows how to power California with wind, water and sun 4The microbes make the sake brewery 2UTHealth Dr. Bhavani Iyer awarded low vision grant 2
... with millions of enamel-eroding, gum-inflaming microbes. , One of ... a claim deep within the spaces between teeth and ... ?secreting proteins that destroy the soft tissues and bone ... scientists have identified the thousands of proteins the bacterium ...
... of arboreal animals have learned to glide through the ... and even ?frightening as it sounds ?snakes. , Now, ... University of California, Berkeley, and the University of Texas ... only wingless insects known to actively direct their fall ...
... into ribonucleic acids (RNA)--the building blocks of life--is exploding ... genetics, health, disease and the development of organisms. The ... for researchers to develop a shared vocabulary and system ... international team of RNA scientists, known as the RNA ...
Cached Biology News:UF Researchers Map Bacterial Proteins That Cause Tooth Loss 2UF Researchers Map Bacterial Proteins That Cause Tooth Loss 3Falling ants glide back to trunk to avoid dangers of forest floor 2Falling ants glide back to trunk to avoid dangers of forest floor 3Falling ants glide back to trunk to avoid dangers of forest floor 4Falling ants glide back to trunk to avoid dangers of forest floor 5RNA project to create language for scientists worldwide 2RNA project to create language for scientists worldwide 3
Bovine Serum Albumin Heat Shock Diagnostic Grade Powder...
MpV17 transgene, murine homolog, glomerulosclerosis...
... the premium quality siRNAs you need for ... be readily ordered online by providing either ... providing the sense and antisense siRNA sequences. ... Silencer Pre-designed siRNAs, which are already designed ...
Human SDNSF/MCFD2 Biotinylated Affinity Purified PAb...
Biology Products: